---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-003500"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T10:27:16.670193+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Dermata Therapeutics reports FY 2023 net loss; cash runway into Q3 2024; Phase 3 acne trial underway

## Summary
- Cash and equivalents $7.4M as of Dec 31, 2023 vs $6.2M in 2022; expects to fund ops into Q3 2024.
- Net proceeds of $7.6M from three 2023 financings partially offset $6.4M cash used in operations.
- R&D expenses $4.1M in 2023 (down from $5.7M in 2022) due to lower clinical costs offset by CMC for Phase 3.
- Enrollment initiated in DMT310 Phase 3 STAR-1 acne trial in Q4 2023; topline results expected Q1 2025.
- Japanese patent issued for DMT410 for hyperhidrosis; partnership discussions ongoing.

## SEC filing metadata
- accession: 0001654954-24-003500
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000165495424003500/0001654954-24-003500-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000165495424003500/drma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-003500
- JSON: https://secwatch.observer/filing/0001654954-24-003500.json
- Plain text: https://secwatch.observer/filing/0001654954-24-003500.txt

## Key facts
- Earnings Releases
  Dermata Therapeutics, Inc. reported financial results for full year ended December 31, 2023.
  - Period: full year ended December 31, 2023
  - Result: reported results
  source text: On March 21, 2024, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1853816/000165495424003500/0001654954-24-003500-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.